Literature DB >> 10634811

Oxidized VLDL induces less triglyceride accumulation in J774 macrophages than native VLDL due to an impaired extracellular lipolysis.

M C Jong1, W L Hendriks, L C van Vark, V E Dahlmans, J E Groener, L M Havekes.   

Abstract

The present study examined the relative contributions of the different pathways by which oxidatively modified VLDL (oxVLDL) promotes the uptake and intracellular accumulation of lipids in J774 macrophages. VLDL was oxidized for a maximum of 4 hours, resulting in an increase in thiobarbituric acid-reactive substances and an increased electrophoretic mobility on agarose gel. The lipid composition of the relatively moderately oxidized VLDL samples did not differ significantly from that of nonoxidized VLDL samples. The uptake of (125)I-labeled VLDL by the J774 cells increased with oxidation time and was completely blocked on coincubation with polyinosinic acid (PolyI), indicating that oxVLDL is taken up by the cells via the scavenger receptor only. Despite the 2-fold increased uptake of oxVLDL protein, the cell association of triglyceride (TG)-derived fatty acids by the J774 macrophages after incubation with oxVLDL was only 50% of that with native VLDL. In line with these observations, the induction of de novo synthesis of TG by J774 cells was approximately 3-fold less efficient after incubation with oxVLDL than after incubation with native VLDL. The induction of de novo synthesis of TG with oxVLDL was even further decreased on simultaneous incubation with PolyI, whereas PolyI did not affect the native VLDL-induced TG synthesis. These results indicate that oxVLDL induces endogenous TG synthesis predominantly through particle uptake via the scavenger receptor and much less via the extracellular lipoprotein lipase (LPL)-mediated hydrolysis of TG, as is the case for native VLDL. In line with these observations, we showed that the suitability of VLDL as a substrate for LPL decreases with oxidation time. Addition of oxVLDL to the LPL assay did not interfere with the lipolysis of native VLDL. However, enrichment of the oxidized lipoprotein particle with native apoC2 was able to fully restore the impaired lipolysis. Thus, from these studies it can be concluded that on oxidation, VLDL becomes less efficient in inducing TG accumulation in J774 cells as a consequence of a defect in apoC2 as an activator for the LPL-mediated extracellular lipolysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634811     DOI: 10.1161/01.atv.20.1.144

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  4 in total

1.  Macrophage adipose triglyceride lipase deficiency attenuates atherosclerotic lesion development in low-density lipoprotein receptor knockout mice.

Authors:  Bart Lammers; Prakash G Chandak; Elma Aflaki; Gijs H M Van Puijvelde; Branislav Radovic; Reeni B Hildebrand; Illiana Meurs; Ruud Out; Johan Kuiper; Theo J C Van Berkel; Dagmar Kolb; Guenter Haemmerle; Rudolf Zechner; Sanja Levak-Frank; Miranda Van Eck; Dagmar Kratky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-28       Impact factor: 8.311

2.  Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase.

Authors:  Prakash G Chandak; Branislav Radovic; Elma Aflaki; Dagmar Kolb; Marlene Buchebner; Eleonore Fröhlich; Christoph Magnes; Frank Sinner; Guenter Haemmerle; Rudolf Zechner; Ira Tabas; Sanja Levak-Frank; Dagmar Kratky
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

3.  VLDL Induced Modulation of Nitric Oxide Signalling and Cell Redox Homeostasis in HUVEC.

Authors:  Maria Chiara Magnifico; Roxana Elena Oberkersch; Azzurra Mollo; Luca Giambelli; Yasmine Grooten; Paolo Sarti; Graciela Cristina Calabrese; Marzia Arese
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

4.  Lipoprotein markers associated with disability from multiple sclerosis.

Authors:  A R Gafson; T Thorne; C I J McKechnie; B Jimenez; R Nicholas; P M Matthews
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.